WuXi Biologics to support Vertex’s autoimmune TCE R&D with full CRDMO integration
Vertex licenses trispecific TCE from WuXi Biologics for autoimmune drug R&D. Explore platform risks, modality fit, and strategic expansion in this analysis.
FAR Biotech expands to Madison: What this means for AI-based drug development
FAR Biotech brings its QuantumAI platform to Madison. Find out what this move means for drug discovery, platform scalability, and Wisconsin’s biohealth future.
Lilly and NVIDIA commit $1bn to AI co-innovation lab for next-gen drug discovery
Eli Lilly and Company and NVIDIA have announced the formation of a co-innovation lab aimed at accelerating drug discovery using AI, robotics, and advanced compute. With a planned $1 billion investment over five years, the lab will leverage NVIDIA’s BioNeMo platform and Vera Rubin architecture alongside Lilly’s drug development expertise. The initiative represents one of […]
Pierre Fabre and Iktos partner on AI-designed small-molecule cancer therapies
Pierre Fabre joins forces with Iktos to discover AI-designed oncology drugs. Find out what this means for cancer R&D, regulatory strategy, and pipeline speed.
M&G backs bit.bio with $50m Series C to accelerate NAMs and AI-ready cell models
bit.bio raised $50M to expand its human cell programming platform for toxicology and AI model training. Find out why investors are backing NAMs now.
What is the regulome, and why is it becoming biotech’s new battleground?
Discover how biotech startups are targeting the regulome—the cell’s regulatory code—to unlock new drug targets beyond the genome and proteome.
Will AI-native drug discovery platforms create a new biotech category in 2026?
As 2026 begins, a new class of biotechnology companies is gaining prominence, not for any single drug, but for how they discover them. These firms, often referred to as AI-native biotechs, are reengineering the drug discovery process around machine learning. Unlike traditional pharmaceutical companies that apply algorithms to specific decision points in an existing workflow, […]
The undruggable no more? Inside the new wave of PPI inhibitors in cancer and fibrosis
In the decades-long war against disease, pharmaceutical companies have learned to build drugs like locksmiths—designing compounds that fit neatly into molecular pockets, disabling enzymes and receptors with surgical precision. But not every biological lock comes with a keyhole. Protein–protein interactions, or PPIs, often involve broad, flat, and shifting surfaces that refuse to conform to conventional […]
Meiji Seika Pharma’s alliance with MBC BioLabs signals a bold shift in global R&D sourcing strategy
Meiji Seika Pharma Co., Ltd. has announced a strategic partnership with MBC BioLabs, a leading biotech incubator based in California’s San Francisco Bay Area, to expand its global drug discovery initiatives. The Tokyo-headquartered pharmaceutical firm aims to deepen its open innovation approach by tapping into early-stage biotech talent in the United States, with a focus […]
Can OTR Therapeutics give Zealand Pharma an edge in non-peptide metabolic therapies?
Zealand Pharma A/S and OTR Therapeutics have entered a multi-program strategic collaboration and licensing agreement to develop novel oral small-molecule therapies for metabolic diseases. The deal includes an initial payment of USD 20 million to OTR Therapeutics, which could increase to USD 30 million under predefined conditions. Total consideration may reach approximately USD 2.5 billion, […]